BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10092013)

  • 1. Immunogenicity of variable regions of hepatitis C virus proteins: selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA.
    Rodr Guez-L Pez M; Riezu-Boj JI; Ruiz M; Berasain C; Civeira MP; Prieto J; Borr S-Cuesta F
    J Gen Virol; 1999 Mar; 80 ( Pt 3)():727-738. PubMed ID: 10092013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the antibody reactivity to synthetic peptides from different parts of the hepatitis C virus genome.
    Pujol FH; Khudyakov YE; Devesa M; León G; Blitz-Dorfman L; Monsalve F; Lambert SB; Kalinina TY; Liprandi F; Fields HA
    Viral Immunol; 1996; 9(2):89-96. PubMed ID: 8822625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Reactivity of Synthetic Peptides Originated from Hypervariable Region 1 of Hepatitis C Synthetic Consensuses with Egyptian Sera Infected with Hepatitis C Virus Type 4.
    Abdel-Fattah M; Charmy R; Tawfik AR
    Intervirology; 2015; 58(4):232-41. PubMed ID: 26330263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunoreactivity studies on synthetic peptides deriving from immunodominant region of hepatitis C virus NS5a gene].
    Shi LL; Dou XG; Feng GH; Fields H; Khudyakov Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Dec; 18(4):344-7. PubMed ID: 15650785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral immunity to immunodominant epitopes of Hepatitis C virus in individuals infected with genotypes 1a or 1b.
    Carlos MP; Yamamura Y; Vu Q; Conzen K; Anderson DE; Torres JV
    Clin Immunol; 2004 Apr; 111(1):22-7. PubMed ID: 15093548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the full-length HCV core subgenome from HCV gentoype-1a and genotype-3a and evaluation of the antigenicity of translational products.
    Ansari MA; Irshad M; Agarwal SK; Chosdol K
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):806-13. PubMed ID: 23442416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C.
    López-Labrador FX; He XS; Berenguer M; Cheung RC; González-Candelas F; Wright TL; Greenberg HB
    J Med Virol; 2004 Apr; 72(4):575-85. PubMed ID: 14981760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic variation of core, NS3, and NS5 proteins among genotypes of hepatitis C virus.
    Neville JA; Prescott LE; Bhattacherjee V; Adams N; Pike I; Rodgers B; El-Zayadi A; Hamid S; Dusheiko GM; Saeed AA; Haydon GH; Simmonds P
    J Clin Microbiol; 1997 Dec; 35(12):3062-70. PubMed ID: 9399495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype dependence of hepatitis C virus antibodies detectable by the first-generation enzyme-linked immunosorbent assay with C100-3 protein.
    Nagayama R; Tsuda F; Okamoto H; Wang Y; Mitsui T; Tanaka T; Miyakawa Y; Mayumi M
    J Clin Invest; 1993 Sep; 92(3):1529-33. PubMed ID: 7690782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a multiple peptide assay for typing of antibodies to the hepatitis C virus: relation to genomic typing by the polymerase chain reaction.
    Zhang ZX; Yun ZB; Chen M; Sönnerborg A; Sällberg M
    J Med Virol; 1995 Jan; 45(1):50-5. PubMed ID: 7536231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia.
    Gabrielli A; Zhang ZX; Cherubini G; Candela M; Savoldi S; Manzin A; Clementi M; Amoroso A; Sallberg M
    Clin Exp Immunol; 1996 Jul; 105(1):59-64. PubMed ID: 8697636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of human immune response to potential hepatitis C viral epitopes.
    Khanna A; Poduri CD; Murugan P; Kumar S; Sugunan VS; Shenoy KT; Das MR
    Acta Virol; 1998 Jun; 42(3):141-5. PubMed ID: 9842443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood.
    Beld M; Penning M; van Putten M; Lukashov V; van den Hoek A; McMorrow M; Goudsmit J
    Hepatology; 1999 Apr; 29(4):1288-98. PubMed ID: 10094977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3.
    Simmonds P; Rose KA; Graham S; Chan SW; McOmish F; Dow BC; Follett EA; Yap PL; Marsden H
    J Clin Microbiol; 1993 Jun; 31(6):1493-503. PubMed ID: 7686182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diverse patterns of recognition of hepatitis C virus core and nonstructural antigens by antibodies present in Egyptian cancer patients and blood donors.
    Attia MA; Zekri AR; Goudsmit J; Boom R; Khaled HM; Mansour MT; de Wolf F; el-Din HM; Sol CJ
    J Clin Microbiol; 1996 Nov; 34(11):2665-9. PubMed ID: 8897161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype dependence of peptide-based immunoassays for the detection of HCV core antibodies.
    Muerhoff AS; Gutierrez R; Kyrk C; Leary T; Schlauder G; Dawson G; Desai SM
    J Med Virol; 2008 Mar; 80(3):411-8. PubMed ID: 18205228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
    Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
    PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes.
    Erickson AL; Kimura Y; Igarashi S; Eichelberger J; Houghton M; Sidney J; McKinney D; Sette A; Hughes AL; Walker CM
    Immunity; 2001 Dec; 15(6):883-95. PubMed ID: 11754811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy.
    Park YM; Byun BH; Choi JY; Bae SH; Kim BS; So HS; Ryu WS
    J Korean Med Sci; 1999 Apr; 14(2):165-70. PubMed ID: 10331562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The quantitative humoral immune response to the hepatitis C virus is correlated with disease activity and response to interferon-alpha.
    Löhr HF; Elste C; Dienes HP; Michel G; Braun HB; Meyer zum Büschenfelde KH; Gerken G
    J Hepatol; 1996 Sep; 25(3):292-300. PubMed ID: 8895007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.